Aug 2026· Bone & Joint Open· Vol 7, pp. 1110 - 1117· 0 citations· 22 references
Medicine
TL;DR
NOF-like lesions are frequent on whole-body MRI scans of NF1 patients, however, there is no association with clinical symptoms.
Abstract
Aims Neurofibromatosis type 1 (NF1) is genetic syndrome involving multiple tissues and organs including the skeleton. Because of prevalent tumours, NF1 patients often receive an MRI scan for the whole body. On MRI, skeletal findings resembling nonossifying fibroma (NOF) are frequently found. The clinical relevance of these lesions is unknown, so that diagnosis often leads to uncertainty for patients and physicians. The present study aims to explore the frequency of MRI-detectable NOF-like lesions and retrospectively evaluate associated clinical symptoms. Methods A total of 333 NF1 patients who received at least one whole-body MRI were included. These MRI scans were assessed by a radiologist and an orthopaedic surgeon for NOF-like signals. For patients with NOF-like findings, medical records were re-evaluated to identify associated clinical symptoms. Results A total of 127 NOF-like lesions were observed in 63 out of the 333 patients (19%). The most frequent region of the radiological lesions was the femur (57%), followed by the tibia (25%). Histology of two such lesions were NOF and fibrous dysplasia. For the majority (84%) of the patients with such NOF-like lesions, no associated symptoms were identified. Ten patients (16%) had mild transient symptoms in the proximity of their NOF-like lesions. However, extensive and follow-up examination excluded an association of these symptoms with the radiological lesions. Conclusion NOF-like lesions are frequent on whole-body MRI scans of NF1 patients. However, there is no association with clinical symptoms. No specific treatment is indicated. These NOF-like lesions should be recognized as ‘no-touch’ lesions. Cite this article: Bone Jt Open 2026;7(8):1110–1117.
The results of this cross-sectional study suggest that CAs represent a frequent and previously unrecognized vascular manifestation of NF1, which is supported by epidemiological enrichment and mechanistic evidence of biallelic NF1 inactivation in vascular cells.
L. Fertitta, É. Pasmant, C. Bergqvist et al.· JAMA dermatology· 0 citations
Type 1 neurofibromatosis (NF1) is a common autosomal dominant genetic disorder characterized by various manifestations, including plexiform neurofibromas; retroperitoneal involvement is rare but can complicate diagnosis and management. We report the case of a 42-year-old man presenting with pelvic pain and a left glute...
A. Elmoctar, M. Ouazine, H. Bello et al.· Scholars Journal of Medical...· 0 citations
Background: Hemangioblastomas (HBs) are benign, highly vascular tumors that predominantly arise in the posterior fossa and are typically associated with von Hippel–Lindau disease. Their occurrence in individuals with neurofibromatosis type 1 (NF1) is exceptional and represents a diagnostic challenge. Case Description:...
An evidence-informed and clinically oriented framework for management of NF1-associated PNs is provided, complementary to existing international recommendations, and offers practical guidance in areas where evidence remains limited.
C. Santoro, E. Arkhangelskaya, Ambra Bonvicino et al.· Neurological Sciences· 0 citations
While surgical boundaries remain highly restricted in deep-tissue infiltrative PN, the introduction of targeted MEK inhibitors marks a pivotal therapeutic paradigm shift and improving timely access to these therapies may help prevent further functional deterioration in selected pediatric patients.
Pseudomyogenic hemangioendothelioma (PHE) is a rare vascular neoplasm of intermediate malignant potential that predominantly affects young adult men and most frequently arises in the lower extremities. Involvement of unusual skeletal sites is uncommon, and the nonspecific imaging features of PHE may contribute to d...
Mei-Zheng Dang, Bu-Yi Zhang, Wen Xu et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.